🔥 Trending Ebola Vaccine Trials: Latest Updates and Developments

Recent developments in Ebola vaccine trials, particularly in late 2026, show significant progress, especially in response to ongoing outbreaks in the Democratic Republic of the Congo (DRC) and Uganda ¹⁷. A key focus is on the Bundibugyo ebolavirus (BDBV) strain, which has historically lacked a specific vaccine ⁶.

Key Developments in Ebola Vaccine Trials

Bundibugyo Ebolavirus (BDBV) Vaccine Trials

The most notable progress involves the development and testing of vaccines specifically targeting the Bundibugyo strain of Ebola. This strain is responsible for the largest recorded outbreak in the DRC ¹.

• University of Oxford's BD-Ebov Trial: The University of Oxford's Oxford Vaccine Group launched the world's first Phase I clinical trial for a Bundibugyo ebolavirus vaccine, named BD-Ebov, in July 2026 ⁶⁷.
• The first volunteer was vaccinated on July 24, 2026 ⁶.
• Researchers aim to test this vaccine in outbreak scenarios in Uganda later in 2026 ².
• This trial is a direct response to the ongoing outbreak in the DRC and neighboring Uganda ⁷.
• The lead scientist, Teresa Lambe, highlighted the speed at which the team moved to initiate the trial ².

• Moderna's mRNA-1777 Vaccine: Moderna also initiated a Phase 1 clinical trial for its mRNA-1777 vaccine, designed to target the Bundibugyo strain, in August 2026 ⁴¹⁰.
• This trial aims to assess the safety and immunogenicity of the vaccine ⁴.

Broader Ebola Vaccine Research

Beyond the Bundibugyo strain, general efforts continue to advance Ebola vaccine development and testing for other strains.

• Inactivated Ebola Vaccine Studies: A Phase 1 study in Japan evaluated an inactivated Ebola virus vaccine in healthy volunteers, focusing on its safety and immunogenicity ³.
• Safety and Immunogenicity of Existing Vaccines: Randomized, controlled trials in Liberia have assessed the safety and immunogenicity of two vaccines against Ebola virus disease, finding no safety signals ⁵.
• Heterologous Vaccine Approaches: Research has also explored heterologous prime-boost regimens, such as cAd3-Ebola and MVA-EbolaZ vaccines. These have shown to be safe and immunogenic, though MVA-EbolaZ generated lower antibody titers than cAd3-Ebola in naïve participants ⁸.
• Past Vaccine Development: Earlier efforts, as far back as 2015, saw the World Health Organization (WHO) announcing acceptable safety profiles for vaccines like cAd3-EBO Z and VSV-EBOV during early tests ⁹.

Current Outbreak Context

The urgency for these vaccine trials is underscored by the ongoing Ebola outbreak in the DRC, which is described as the largest ever recorded in the country. The World Health Organization (WHO) has highlighted that while results from new vaccine trials may take months, efforts are progressing towards enhanced treatment and the world's first vaccine for the Bundibugyo species of Ebola ¹.